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LETTERS TO THE EDITOR
Vasomotor Effects and
Pathophysiologic Relevance of
F2-Isoprostane Formation in Vascular Diseases
We read with the utmost interest the study by Iuliano et al. (1).
The investigators showed for the first time that concentrations of
2-F2-isoprostane regioisomers, iPF2-III (15-F2t-IsoP) and
iPF2-VI (5-F2t-IsoP), were markedly increased in the coronary
sinus following percutaneous transluminal coronary angioplasty
(PTCA). In their study, the levels of iPF2-III in the coronary
sinus after angioplasty, measured by GC/NICI-MS, were 125
pg/ml, which is equivalent to 0.35 nmol/l. Such levels are in the
same range as plasma samples in nonsmokers (0.103 nmol/l [2], in
ruptured aortic aneurysm 0.436 nmol/l [3]) and umbilical cord
arterial samples in newborns (0.898 nmol/l [4]), although caution
should be taken when comparing these results as the methodology
used to measure iPF2-III was different. Such data do not support
the conclusion that these concentrations are similar to the EC50
values observed with iPF2-III on porcine and bovine coronary
arteries that are in the micromolar range (5). Indeed, the potency
of iPF2-III was in the micromolar range in most studies per-
formed on conductance vessels, including coronary arteries (6),
although data on human coronary arteries are lacking.
Consequently, the concentrations observed in this study (1) are
unlikely to induce a vasoactive effect in conductance vessels. In
contrast, the potency of iPF2-III in the microcirculation is higher,
and in some studies close to the nanomolar range (6). As a
consequence, whereas the concentrations reported in the Iuliano
et al. study (1) are unlikely to contribute to epicardial coronary
artery vasoconstriction, local concentrations may be sufficiently
high to induce intramyocardial artery vasoconstriction. Further in
vivo and in vitro studies are required to determine whether
isoprostanes might contribute to vasoconstriction in vascular dis-
eases.
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REPLY
Cracowski et al. raise an important issue related to the putative
biologic effect of F2-isoprostanes (iPs) in human coronary arteries
after percutaneous transluminal coronary angioplasty (PTCA). We
observed an increase of isoprostanes iPF2-III and iPF2-VI in the
coronary sinus immediately after PTCA and suggested that this
elevation not only reflected reperfusion-mediated oxidative stress
but could also play a role in the untoward effects of this procedure.
In particular, iPs may facilitate platelet activation and coronary
vasospasm, two phenomena that occur early after PTCA and are
responsible for coronary thrombosis and arrhythmia.
Used as markers of oxidant stress, F2-iPs are increased not only
in clinical settings associated with ischemia-reperfusion but also in
settings characterized by chronic inflammation such as atheroscle-
rosis, chronic bronchitis and systemic lupus erythematosus (1–3).
The F2-iPs may also have biologic relevance because they enhance
platelet response to the common agonists and elicit a vasomotor
response. However, it is still unclear whether these effects can
occur in clinical settings associated with enhanced oxidative stress.
An in vitro study demonstrated that iPF2-III was not able to elicit
platelet aggregation, but in a range of concentration between 10
nmol/l and 10 mol/l increased the magnitude of platelet response
to subthreshold concentrations of arachidonic acid, collagen and
adenosine diphosphate (ADP) (4). Patients with diabetes and
hypercholesterolemia show a significant correlation between
iPF2-III and 1-dehydrothromboxane B2 values, suggesting a
potential link between platelet aggregation and lipid peroxidation
(5,6). This was corroborated by the concomitant decrease of
iPF2-III and 11-dehydrothromboxane B2 in patients given 100 to
600 mg/d vitamin E. These data suggest that the circulating levels
of iPF2-III may be relevant to clinical settings in which platelet
activation and enhanced oxidative stress coexist. Because these two
phenomena coincide after PTCA, it is conceivable that a link exists
between them, taking into account that in some patients the
circulating levels of iPF2-III after PTCA were close to 1 nmol/l.
We agree with Cracowski and colleagues that the circulating levels
of iPF2-III were likely too low to elicit a direct vasomotor
response in the coronary circulation. However, values of the two
isoprostane regioisomers measured specifically by us in the coro-
nary sinus cannot be extrapolated to Morrow et al.’s (7) total
isoprostane assay with PGF2 as internal standard. Even if it did
give a quantitative impression of total iPs, this method is quanti-
tatively imprecise, measuring a host of unresolved peaks. Similar
amounts of one isoprostane, such as iPF2-III, which is not a very
abundant one, suggests that an accurate estimate of total iPs in the
coronary circulation would be much higher than in peripheral
plasma. Also, it is very difficult to extrapolate from one iP to the
effects and local concentration of myriad ones released at the site of
free radical burst on the vascular wall.
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Finally, it has never been studied, as in the case of platelet
aggregation, whether iPF2-III is able to amplify the vasomotor
response to other agonists. This effect should be studied in the
future before concluding that the concentration of this isoprostane
in the coronary circulation has no role in the vasospasm occurring
after PTCA.
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Percutaneous Revascularization Versus
Beating Heart CABG or CABG With
Cardiopulmonary Bypass in Patients
With Refractory Myocardial Ischemia
Morrison et al. (1) recently reported the results of a very important
multicenter randomized trial comparing percutaneous coronary
intervention (PCI) versus coronary artery bypass graft surgery
(CABG) for patients with refractory myocardial ischemia and risk
factors for adverse outcomes with CABG. It clearly appears that
PCI is an alternative to CABG for patients with medically
refractory myocardial ischemia at high risk for adverse outcomes
with CABG. Incidentally, the study was initiated in February 1995
when multivessel beating heart CABG via sternotomy was popu-
larized by Buffolo et al. (2). The study by Morrison et al. (1) does
not address the techniques used to accomplish CABG in this
study. If CABG was performed using cardiopulmonary bypass,
then the study fails to mention the cardioprotective strategies used,
as this may be an important factor in the rates of perioperative
myocardial infarction (MI) and clinical outcomes (3). Unless strict
cardioprotective criteria were used, it is indeed possible that various
surgeons from various centers used different cardioprotective strat-
egies: ventricular fibrillation versus ischemia, crystalloid versus
blood cardioplegia, antegrade versus retrograde delivery of cardio-
plegia and warm versus cold cardioplegia (3). In addition, the
methods fail to mention whether off-pump CABG was utilized,
and if so, for which type of patients. Although initial results of
off-pump CABG in low-risk patients is encouraging, patients with
high preoperative risk factors (octogenarians, recent MI, reopera-
tive CABG, left ventricular ejection fraction 40%, previous
stroke) seem to derive marked advantages from the off-pump
technique (4). Prospective randomized trials with longitudinal
clinical and angiographic follow-up are needed to better define the
real advantages and limits of this new clinical strategy in all
patients, especially in high-risk groups. Preliminary data at mid-
term follow-up is very encouraging for coronary revascularization
on the beating heart (5–8).
Finally, if these studies are further corroborated, then the
surgical strategy itself (beating heart versus traditional CABG
using cardiopulmonary bypass) may prove to be an additional
factor in comparisons of revascularization methods in high-risk
patients. We commend Morrison et al. (1) for conducting a very
important and timely study.
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